WuXi XDC Cayman Inc operates as an investment holding company and a global contract research development and manufacturing organization CRDMO with operations spanning China North America Europe and other international regions The companys expertise covers the entire lifecycle from discovery and research to development and manufacturing of biopharmaceutical products Specifically it focuses on antibodydrug conjugates ADCs various bioconjugates monoclonal antibody intermediates and the crucial payloadlinkers integral to bioconjugate synthesis Founded in 2013 and headquartered in Wuxi China WuXi XDC Cayman Inc is a subsidiary of WuXi Biologics Cayman Inc
Financial Ratios (TTM)
Gross Margin
35.99%
Operating Margin
27.27%
Net Margin
24.91%
ROA
10.25%
Price to Book
5.02
Price to Sales
8.55
We value your privacy
We use cookies to analyze traffic and show ads. Accept all cookies, or continue with only the essential ones. Learn more